



Article

The Risk Factors for Development of Type 2 Diabetes: Panasonic Cohort Study 4

Yuto Saijo ¹, Hiroshi Okada ^{2,*}, Masahide Hamaguchi ¹, Momoko Habu ², Kazushiro Kurogi ³, Hiroaki Murata ⁴, Masato Ito ³ and Michiaki Fukui ¹

- ¹ Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto 602-8566, Japan; y-saijo@koto.kpu-m.ac.jp (Y.S.); mhama@koto.kpu-m.ac.jp (M.H.); michiaki@koto.kpu-m.ac.jp (M.F.)
- ² Department of Diabetes and Endocrinology, Matsushita Memorial Hospital, Moriguchi 570-8540, Japan; habu.momoko@jp.panasonic.com
- ³ Department of Health Care Center, Panasonic Health Insurance Organization, Moriguchi 570-8540, Japan; kurogi.kazushirou@jp.panasonic.com (K.K.); itoh.masato@jp.panasonic.com (M.I.)
- ⁴ Department of Orthopaedic Surgery, Matsushita Memorial Hospital, Moriguchi 570-8540, Japan; murata.hiroaki@jp.panasonic.com
- * Correspondence: conti@koto.kpu-m.ac.jp or continental4x33211@msn.com; Tel.: +81-6-6992-1231; Fax: +81-6-6992-4845

Abstract: (1) Background: As no study has evaluated the risk factors contributing to the development of type 2 diabetes according to body weight mass (BMI) categories in a large cohort and over a long period in a Japanese population, we aimed to assess them in 46,001 Japanese individuals; (2) Methods: This long-term retrospective cohort study included individuals who participated in a medical health checkup program at Panasonic Corporation from 2008 to 2018. In total, 3,208 participants developed type 2 diabetes. The BMI at 2008 were divided into 3 groups: BMI < 22 kg/m², 22 ≤ BMI < 25 kg/m², and BMI ≥ 25 kg/m² to evaluate the risk factors for type 2 diabetes; (3) Results: Cox regression analyses revealed that the significant risk factors were age, BMI, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, fasting plasma glucose, current smoking status, and alcohol consumption in populations with BMI ≥ 25.0 kg/m². The risk factors in the population with 22 ≤ BMI < 25 kg/m² were identical to that of BMI ≥ 25.0 kg/m² excluding systolic blood pressure, low-density lipoprotein cholesterol, and skipping breakfast. However, in the population with BMI < 22.0 kg/m², no association was found as to BMI, SBP, LDL cholesterol level, and triglycerides; (4) Conclusions: The risk factors for developing diabetes were quite different between the population with BMI < 22 kg/m² and the population with 22 ≤ BMI < 25 kg/m² or BMI ≥ 25 kg/m² in a Japanese population.

Keywords: type 2 diabetes; body mass index; database research; cohort study



Citation: Saijo, Y.; Okada, H.; Hamaguchi, M.; Habu, M.; Kurogi, K.; Murata, H.; Ito, M.; Fukui, M. The Risk Factors for Development of Type 2 Diabetes: Panasonic Cohort Study 4. *Int. J. Environ. Res. Public Health* **2022**, *19*, 571. <https://doi.org/10.3390/ijerph19010571>

Academic Editor: Paul B. Tchounwou

Received: 2 December 2021

Accepted: 31 December 2021

Published: 5 January 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

In recent decades, diabetes has become increasingly prevalent globally, causing the health expenditure to pile up. Therefore, preventing the development of diabetes is of great significance and a common concern in clinical settings. Previous studies indicate that multiple risk factors including age, family history, obesity [1], impaired fasting glycemia [2,3], impaired glucose tolerance [2], nonalcoholic fatty liver disease [4], uric acid [5], potassium [6], low lung function [7], smoking status, hypertension, hyperlipidemia, chronic inflammation [8–10], liver enzymes [11,12], lifetime maximum BMI, change in BMI from early adulthood [13], eating speed [14], and lack of sleep [15] accelerate the development of diabetes in the Japanese population. We should identify those who are at a high risk of developing type 2 diabetes. Health guidance for prevention of diabetes is necessary at an early stage of prediabetes.

There are fewer obese people in Japan than in Western countries. BMIs of Japanese patients with diabetes are similar to those of the general Japanese population [16]. Unlike Western populations, pre-diabetes in the Japanese population is characterized by both relatively low insulin secretion and insulin resistance. [17]. It has been reported that Asian subjects developed diabetes at lower ranges of BMI than those of Western populations [18]. In other words, type 2 diabetes is a heterogeneous disease caused by multifactorial etiology in the Japanese population. Because the etiology of diabetes in the Japanese population is characterized by lower insulin secretion and insulin resistance, we thought that diminished insulin secretion might have a direct impact on developing diabetes especially in a lean or non-obese population. Therefore, we believe that the risk factors for the development of diabetes might differ according to BMI categories and its appropriateness among BMI categories has been questioned. We thought that the risk factors for the development of diabetes needed to be evaluated separately according to BMI categories in a Japanese population.

As far as we know, no other study has elucidated the risk factors contributing to the development of type 2 diabetes according to BMI categories in a large cohort and a long period in a Japanese population. Therefore, this study, for the first time, looked into the risk factors for type 2 diabetes in a Japanese population according to BMI categories.

2. Materials and Methods

2.1. Study Design and Data Collection

This is a long-term retrospective cohort study. The subjects consist of corporate employees who received a medical health checkup program conducted in Panasonic Corporation, Osaka, Japan. This program aims to promote public health by detecting as early as possible the signs of chronic diseases including metabolic disorders and evaluating what risk factors underlie them. Every employee participates in this program every year. The employers are required by the Ordinance of the Ministry of Health, Labor and Welfare, to provide employees with medical examinations conducted by a physician. We obtained the data between 2008 and 2018 from the database which we call the Panasonic cohort study.

The blood tests were performed after more than 10 hours of fasting. Height and body weight were recorded using an instrument capable of measuring both automatically. The change in BMI was defined as the delta BMI (BMI in the end of study, which means the development of diabetes or 2018—BMI in 2008). We used the standardized self-administered questionnaire, which has been previously validated, to assess the baseline characteristics in 2008. Smoking status was categorized into current smokers, past smokers, and non-smokers. Eating speed was classified as fast, normal, and slow. We asked participants if they made a habit of eating breakfast or a snack after dinner. Alcohol drinkers were defined by daily consumption of alcohol. Regular exercisers were defined as those who played any sport twice a week regularly. The definition of Type 2 diabetes in this study was as follows: fasting plasma glucose (FPG) level ≥ 126 mg/dL, having a self-reported history of diabetes, and/or the administration of anti-diabetic agents.

This study was approved by the local ethics committee of Panasonic Health Insurance Organization (Approval number: 2021-001) and was conducted in accordance with the principles of the Declaration of Helsinki.

2.2. Exclusion Criteria

A total of 140,590 employees received a medical health checkup in 2008. The participants who did not consecutively receive health checkups from 2008 to 2018 were excluded ($n = 65,256$) from the study. Those with diabetes at baseline were excluded ($n = 4342$). Those with missing data were also excluded ($n = 24,991$).

2.3. Statistical Analyses

We calculated frequencies and the mean values of potential confounding variables. The differences in general characteristics at baseline according to BMI categories were assessed by analysis of variance and chi-square test as appropriate. The BMI were divided

into 3 groups: BMI < 22 kg/m², 22 ≤ BMI < 25 kg/m², and BMI ≥ 25 kg/m² because Japan society for the study of obesity defined 22 kg/m² of BMI as standard BMI, which is associated with the lowest morbidity and defined BMI ≥ 25 kg/m² as obesity [19]. The hazard ratios for the development of type 2 diabetes were calculated by Cox regression analyses using multivariate models. The factors related to the development of type 2 diabetes are selected as covariates included in the multivariate model. The multivariate model was adjusted for age, sex, BMI, systolic blood pressure (SBP), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, uric acid, smoking status, eating speed, snack after dinner, skipping breakfast, alcohol consumption, and physical exercise. We adopted multivariate logistic regression analysis to demonstrate the effects of the change in BMI from 2008 to 2018 on the development of type 2 diabetes in 2018. The covariates in the multiple logistic regression model were all variables in Cox regression analyses plus the change in BMI from 2008 to 2018. The hazard ratios were assessed for the development of type 2 diabetes in patients with BMI < 22 kg/m², 22.0 ≤ BMI < 25.0 kg/m², and BMI ≥ 25.0 kg/m² at baseline. All continuous variables are presented as mean ± SD or absolute number. The differences with *p* value < 0.05 are regarded as statistically significant. The associations are presented as hazard ratios with a 95% confidence interval (CI). We used JMP software, version 10 (SAS Institute, Cary, NC, USA) to perform statistical analyses.

3. Results

Table 1 shows the baseline characteristics of the participants enrolled in this study. In total, 3208 participants among all participants developed type 2 diabetes during the study period. Table 1 also shows the differences in characteristics at baseline according to BMI categories.

Table 1. Characteristics of participants.

| | ALL | BMI < 22.0 kg/m ² | 22.0 ≤ BMI < 25.0 kg/m ² | BMI ≥ 25.0 kg/m ² | <i>p</i> Value |
|--------------------------------------|--------------------|------------------------------|-------------------------------------|------------------------------|----------------|
| N | 46,001 | 17,857 | 16,629 | 11,515 | - |
| Age (y) | 42.06 (6.09) | 41.16 (6.44) | 42.61 (5.83) * | 42.67 (5.72) * | <0.0001 |
| Sex (male/female) | 38,569/7432 | 12,935/4922 | 15,092/1537 | 10,542/973 | <0.0001 |
| Body mass index (kg/m ²) | 23.09 (3.28) | 20.05 (1.38) | 23.36 (0.85) * | 27.43 (2.41) *,# | <0.0001 |
| SBP (mmHg) | 118.45 (13.97) | 113.48 (12.95) | 119.09 (12.97) * | 125.25 (13.83) *,# | <0.0001 |
| DBP (mmHg) | 74.11 (10.67) | 70.44 (9.88) | 74.64 (10.08) * | 79.03 (10.56) *,# | <0.0001 |
| LDL cholesterol (mg/dL) | 123.91 (30.86) | 113.52 (28.93) | 127.17 (29.81) * | 135.29 (30.18) *,# | <0.0001 |
| HDL cholesterol (mg/dL) | 59.20 (14.81) | 65.71 (15.15) | 57.42 (13.42) * | 51.66 (11.54) *,# | <0.0001 |
| Triglycerides (mg/dL) | 114.41 (88.40) | 84.86 (62.17) | 118.69 (84.55) * | 154.04 (109.31) *,# | <0.0001 |
| FPG (mg/dl) | 92.61 (8.75) | 90.40 (8.10) | 93.11 (8.48) * | 95.32 (9.21) *,# | <0.0001 |
| Uric acid (mg/dL) | 5.89 (1.38) | 5.34 (1.29) | 6.06 (1.27) * | 6.50 (1.33) *,# | <0.0001 |
| Smoking (none/past/current) | 23,613/5910/16,478 | 10,019/1872/5966 | 8113/2410/6106 | 5481/1628/4406 | <0.0001 |
| Eating speed (fast/normal/slow) | 15,838/27,032/3131 | 4304/11,691/1862 | 5975/9759/895 | 5559/5582/374 | <0.0001 |
| Snack after dinner (+/−) | 7991/38,010 | 3023/14,834 | 2797/13,832 | 2171/9344 | <0.0001 |
| Skipping breakfast (+/−) | 10,566/35,435 | 4035/13,822 | 3779/12,850 | 2752/8763 | 0.02 |
| Alcohol drinker (+/−) | 11,085/34,916 | 4228/13,629 | 4502/12,127 | 2355/9160 | <0.0001 |
| Physical exercise (+/−) | 7009/38,992 | 2504/15,353 | 2741/13,888 | 1764/9751 | <0.0001 |

Data are presented as mean (standard deviation) or absolute number. SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FPG, fasting plasma glucose. *: *p* < 0.05 vs. BMI < 22.0 kg/m², #: *p* < 0.05 vs. 22.0 ≤ BMI < 25.0 kg/m².

Table 2 shows the unadjusted hazards ratios for the development of diabetes. Table 3 shows the adjusted hazards ratios in multivariate models for the development of diabetes. The significant risk factors for developing diabetes were age, HDL cholesterol, FPG, smoking status, and eating speed in the population with BMI < 22.0 kg/m². The significant risk factors for developing diabetes were age, sex, BMI, HDL cholesterol, triglycerides, FPG, smoking status, skipping breakfast, and alcohol consumption in the popu-

lation with $22.0 \leq \text{BMI} < 25.0 \text{ kg/m}^2$. The significant risk factors for developing diabetes were age, BMI, SBP, LDL cholesterol, HDL cholesterol, triglycerides, FPG, smoking status, and alcohol consumption in the population with $\text{BMI} \geq 25.0 \text{ kg/m}^2$. If we put SBP, LDL cholesterol, HDL cholesterol, triglycerides, and FPG dichotomized into multivariate models, we found that skipping breakfast was significantly associated with developing diabetes in the population with $\text{BMI} < 22.0 \text{ kg/m}^2$ (HR; 1.29, 95% CI; 1.02–1.61, $p = 0.03$), with $22.0 \leq \text{BMI} < 25.0 \text{ kg/m}^2$ (HR; 1.29, 95% CI; 1.11–1.49, $p = 0.0009$), and with $\text{BMI} \geq 25.0 \text{ kg/m}^2$ (HR; 1.14, 95% CI; 1.03–1.28, $p = 0.02$).

Table 2. Unadjusted hazard ratios for development of diabetes.

| | BMI < 22.0 kg/m ² | | 22.0 kg/m ² ≤ BMI < 25.0 kg/m ² | | BMI ≥ 25.0 kg/m ² | |
|--|------------------------------|---------|---|---------|------------------------------|---------|
| | HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value |
| Age (per 1 year) | 1.10 (1.08–1.12) | <0.0001 | 1.08 (1.07–1.10) | <0.0001 | 1.04 (1.03–1.05) | <0.0001 |
| Sex (male) | 3.28 (2.44–4.51) | <0.0001 | 2.12 (1.60–2.89) | <0.0001 | 1.23 (1.03–1.49) | 0.02 |
| Body mass index at baseline (per 1 kg/m ²) | 1.22 (1.13–1.32) | <0.0001 | 1.27 (1.18–1.36) | <0.0001 | 1.18 (1.16–1.19) | <0.0001 |
| Systolic blood pressure (per 1 mmHg) | 1.04 (1.03–1.04) | <0.0001 | 1.02 (1.01–1.02) | <0.0001 | 1.02 (1.02–1.03) | <0.0001 |
| LDL cholesterol (per 1 mg/dL) | 1.01 (1.007–1.01) | <0.0001 | 1.007 (1.005–1.009) | <0.0001 | 1.006 (1.004–1.007) | <0.0001 |
| HDL cholesterol (per 1 mg/dL) | 0.98 (0.98–0.99) | <0.0001 | 0.98 (0.98–0.99) | <0.0001 | 0.98 (0.97–0.98) | <0.0001 |
| Triglycerides (per 1 mg/dL) | 1.003 (1.002–1.004) | <0.0001 | 1.002 (1.0016–1.002) | <0.0001 | 1.001 (1.001–1.002) | <0.0001 |
| Fasting plasma glucose (per 1 mg/dL) | 1.17 (1.16–1.18) | <0.0001 | 1.16 (1.15–1.16) | <0.0001 | 1.13 (1.12–1.13) | <0.0001 |
| Uric acid (per 1 mg/dL) | 1.30 (1.21–1.40) | <0.0001 | 1.18 (1.12–1.23) | <0.0001 | 1.10 (1.06–1.14) | <0.0001 |
| Smoking (past) (ref: none) | 1.35 (0.96–1.85) | 0.08 | 1.33 (1.09–1.61) | 0.004 | 1.00 (0.86–1.16) | 0.99 |
| Smoking (current) (ref: none) | 2.03 (1.66–2.47) | <0.0001 | 1.81 (1.59–2.08) | <0.0001 | 1.34 (1.22–1.48) | <0.0001 |
| Eating speed (slow) (ref: normal) | 0.56 (0.37–0.81) | 0.002 | 0.86 (0.62–1.15) | 0.31 | 0.87 (0.64–1.16) | 0.35 |
| Eating speed (fast) (ref: normal) | 0.9999 (0.80–1.24) | 0.99 | 1.12 (0.98–1.27) | 0.09 | 1.18 (1.08–1.30) | 0.0005 |
| Snack after dinner (yes) (ref: no) | 0.84 (0.64–1.08) | 0.18 | 0.90 (0.76–1.06) | 0.44 | 1.01 (0.89–1.13) | 0.90 |
| Skipping breakfast (yes) (ref: no) | 1.34 (1.09–1.65) | 0.007 | 1.33 (1.16–1.52) | <0.0001 | 1.23 (1.11–1.37) | <0.0001 |
| Alcohol drinker (yes) (ref: no) | 1.65 (1.35–2.01) | <0.0001 | 1.10 (0.96–1.26) | 0.17 | 0.80 (0.70–0.90) | 0.0002 |
| Physical exercise (yes) (ref: no) | 1.21 (0.93–1.55) | 0.15 | 1.11 (0.95–1.30) | 0.19 | 0.96 (0.84–1.09) | 0.52 |

LDL, low-density lipoprotein; HDL, high-density lipoprotein.

The change in BMI was higher in the population without developing diabetes than that with developing diabetes in the population with $\text{BMI} < 22.0 \text{ kg/m}^2$ (0.89 ± 1.44 vs. $0.61 \pm 1.42 \text{ kg/m}^2$; $p < 0.0001$). In contrast, the change in BMI was higher in the population with developing diabetes than that without developing diabetes in the population with $22.0 \leq \text{BMI} < 25.0 \text{ kg/m}^2$ and with $\text{BMI} \geq 25.0 \text{ kg/m}^2$ (0.67 ± 1.54 vs. $0.54 \pm 1.61 \text{ kg/m}^2$; $p = 0.01$ and 0.73 ± 1.77 vs. $0.31 \pm 2.17 \text{ kg/m}^2$; $p < 0.0001$, respectively). In other words, the rate of weight gain is positively correlated with the development of type 2 diabetes in the population with $22.0 \leq \text{BMI} < 25.0 \text{ kg/m}^2$ and with $\text{BMI} \geq 25.0 \text{ kg/m}^2$. However, it is negatively correlated with the development of type 2 diabetes in the population with $\text{BMI} < 22.0 \text{ kg/m}^2$. The multivariate logistic regression analysis revealed that the change in BMI from 2008 to 2018 was associated in the population with $22.0 \leq \text{BMI} < 25.0 \text{ kg/m}^2$ (odds ratio; 1.13, 95% CI; 1.07–1.19, $p < 0.0001$) and with $\text{BMI} \geq 25.0 \text{ kg/m}^2$ (odds ratio; 1.09, 95% CI; 1.01–1.12, $p < 0.0001$). However, the change in BMI from 2008 to 2018 was not associated with the development of type 2 diabetes (odds ratio; 1.04, 95% CI; 0.94–1.16, $p = 0.41$).

Table 3. Multivariate adjusted hazard ratios for development of diabetes.

| | BMI < 22.0 kg/m ² | | 22.0 kg/m ² ≤ BMI < 25.0 kg/m ² | | BMI ≥ 25.0 kg/m ² | |
|--|------------------------------|---------|---|---------|------------------------------|---------|
| | HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value |
| Age (per 1 year) | 1.06 (1.04–1.08) | <0.0001 | 1.04 (1.02–1.05) | <0.0001 | 1.02 (1.007–1.03) | 0.001 |
| Sex (male) | 1.05 (0.72–1.54) | 0.81 | 0.68 (0.49–0.96) | 0.03 | 0.90 (0.73–1.11) | 0.32 |
| BMI at baseline (per 1 kg/m ²) | 1.03 (0.95–1.12) | 0.45 | 1.11 (1.03–1.20) | 0.008 | 1.10 (1.09–1.12) | <0.0001 |
| Systolic blood pressure (per 1 mmHg) | 1.005 (0.998–1.01) | 0.14 | 0.9996 (0.995–1.004) | 0.88 | 1.006 (1.002–1.009) | 0.001 |
| LDL cholesterol (per 1 mg/dL) | 1.003 (0.999–1.006) | 0.10 | 1.002 (0.99998–1.004) | 0.05 | 1.003 (1.002–1.005) | 0.0001 |
| HDL cholesterol (per 1 mg/dL) | 0.99 (0.98–0.998) | 0.01 | 0.99 (0.99–0.998) | 0.008 | 0.99 (0.98–0.99) | <0.0001 |
| Triglycerides (per 1 mg/dL) | 1.0005 (0.999–1.002) | 0.44 | 1.0008 (1.0003–1.001) | 0.0005 | 1.0005 (1.00008–1.0009) | 0.02 |
| Fasting plasma glucose (per 1 mg/dL) | 1.16 (1.15–1.17) | <0.0001 | 1.16 (1.15–1.16) | <0.0001 | 1.12 (1.11–1.13) | <0.0001 |
| Uric acid (per 1 mg/dL) | 0.99 (0.91–1.07) | 0.75 | 1.05 (0.997–1.11) | 0.06 | 0.98 (0.94–1.01) | 0.23 |
| Smoking (past) (ref: none) | 0.89 (0.63–1.24) | 0.49 | 1.16 (0.95–1.42) | 0.13 | 1.08 (0.92–1.25) | 0.35 |
| Smoking (current) (ref: none) | 1.66 (1.32–2.08) | <0.0001 | 1.999 (1.73–2.31) | <0.0001 | 1.51 (1.36–1.68) | <0.0001 |
| Eating speed (slow) (ref: normal) | 0.65 (0.42–0.96) | 0.03 | 0.97 (0.70–1.31) | 0.86 | 1.05 (0.76–1.40) | 0.77 |
| Eating speed (fast) (ref: normal) | 0.98 (0.78–1.22) | 0.85 | 1.10 (0.96–1.25) | 0.16 | 1.09 (0.99–1.20) | 0.08 |
| Snack after dinner (yes) (ref: no) | 1.03 (0.77–1.36) | 0.82 | 0.93 (0.78–1.11) | 0.43 | 1.05 (0.93–1.18) | 0.44 |
| Skipping breakfast (yes) (ref: no) | 1.12 (0.89–1.40) | 0.34 | 1.20 (1.04–1.39) | 0.02 | 1.006 (0.90–1.12) | 0.91 |
| Alcohol drinker (yes) (ref: no) | 1.04 (0.83–1.30) | 0.72 | 0.75 (0.65–0.87) | 0.0001 | 0.73 (0.64–0.83) | <0.0001 |
| Physical exercise (yes) (ref: no) | 1.08 (0.83–1.40) | 0.55 | 1.16 (0.98–1.37) | 0.08 | 0.93 (0.81–1.07) | 0.31 |

BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein.

4. Discussion

The significant risk factors for the developing diabetes were different among BMI categories. In the population with BMI ≥ 25.0 kg/m², age, obesity, hypertension, hyperlipidemia, FPG level, and smoking status were associated with the development of type 2 diabetes, which have been well known as risk factors for developing diabetes. The significant risk factors for developing diabetes in the population with 22.0 ≤ BMI < 25.0 kg/m² were almost identical to those of BMI ≥ 25.0 kg/m². In contrast, in population with BMI < 22.0 kg/m², BMI, SBP, LDL cholesterol level and triglycerides were not associated with the development of type 2 diabetes. Instead, an association with age, HDL cholesterol level, FPG level, smoking status and eating speed were observed in this population. The major finding of this study is that the risk factors for developing diabetes significantly vary between the population with BMI < 22.0 kg/m² and the population with 22.0 ≤ BMI < 25.0 kg/m² or BMI ≥ 25.0 kg/m² in a Japanese population.

Type 2 diabetes is well known to have heterogeneous etiology in the Japanese population. The difference in risk factors between each BMI category implies that they are different in etiology. It has been well established that type 2 diabetes originates from relative insulin deficiency and/or insulin resistance. There are some studies indicating that obesity induces chronic inflammation [20] and insulin resistance [21,22]. Insulin resistance is partly attributed to the dysregulation of adipocytes, which produce and secrete several cytokines called adipocytokines, e.g., tumor necrosis factor-α (TNF-α), adiponectin, leptin, and plasminogen activator inhibitor-1 (PAI-1) [23,24]. TNF-α develops insulin resistance, whereas adiponectin improves insulin sensitivity. Weight gain is associated with increased visceral adipose tissue, causing the adipocytes to produce more TNF-α and less adiponectin. As a result, higher BMI contributes to insulin resistance and subsequent relative insulin deficiency, culminating in hyperglycemia. These factors play a key role in metabolic syndrome, which refers to a set of metabolic disruptions including visceral obesity, hyperglycemia, dyslipidemia, and hypertension, which are closely related to each other [25]. In our study, dyslipidemia and hypertension were also associated with devel-

oping diabetes in the population with $\text{BMI} \geq 25.0 \text{ kg/m}^2$. Thus, as for population with $\text{BMI} \geq 25.0 \text{ kg/m}^2$, because they are obese, they are more likely to have higher insulin resistance compared to the population with $\text{BMI} < 22$, and once a chronic inflammatory state has been created, these metabolic disruptions fall into a vicious cycle. Interestingly, the same applies to the population with $22.0 \leq \text{BMI} < 25.0 \text{ kg/m}^2$, although they are within the range of normal weight. This result suggests that weight gain and a metabolic disorder in patients within a normal weight range can raise the possibility of developing diabetes. In contrast, for the population with $\text{BMI} < 22$, dyslipidemia, hypertension, or even body weight are not significant risk factors for diabetes. Hyperglycemia in the absence of obesity probably means diminished insulin secretion. Diminished insulin secretion is characteristic of patients with diabetes in Asian countries [26], where BMIs of patients are not remarkably greater than those of the general population [16]. They are possibly more susceptible to reduced insulin secretion and aging than the other populations. Interestingly, the change in BMI was higher in the population without developing diabetes than that with developing diabetes in the population with $\text{BMI} < 22.0 \text{ kg/m}^2$ in this study, which might mean diminished insulin secretion. Smoking is one of the risk factors for type 2 diabetes, as proven by previous studies [27]. Our study reinforces the evidence by showing that regardless of BMI, smoking is a strong risk factor for diabetes.

The westernization of eating habits started after World War II in Japan. Therefore, we suppose that eating habits are one of the most important factors causing higher BMI and developing diabetes in the Japanese population. In terms of eating habits, our study showed that eating speed and alcohol consumption had a protective effect in the population with $\text{BMI} < 22.0 \text{ kg/m}^2$ and with $22.0 \leq \text{BMI} < 25.0 \text{ kg/m}^2$ or with $\text{BMI} \geq 25.0 \text{ kg/m}^2$, respectively. There are some studies reporting that eating fast is associated with obesity [28]. People who eat fast tend to consume more food before they achieve satiety, resulting in the increase in total energy intake. Moreover, eating fast is reported to adversely affect the postprandial glucose excursion [29], which would lead to the impairment of insulin secretion. Especially in lean or non-obese populations ($\text{BMI} < 22.0 \text{ kg/m}^2$), insulin secretion might be relatively low compared to that of other populations. This is probably why eating slow showed a protective effect on developing type 2 diabetes in the population of $\text{BMIs} < 22.0 \text{ kg/m}^2$ in our study. As for alcohol consumption, there is no consistent evidence that alcohol itself has a protective effect on developing diabetes. How alcohol consumption influences the risk of type 2 diabetes might depend on the dose or the type of alcohol [30]. High alcohol consumption causes liver dysfunction, ultimately liver cirrhosis, which increases the risk of type 2 diabetes. Red wine contains antioxidants which might have a protective effect on developing diabetes. Another hypothesis is that alcohol drinkers consume a less balanced diet than non-drinkers, possibly leading to less energy intake.

In Japan, a nationwide screening program was introduced to identify the subjects with obesity ($\text{BMI} \geq 25.0 \text{ kg/m}^2$) and risk factors of cardiovascular disease and to provide health guidance to prevent the development and progression of metabolic disorders and cardiovascular disease among the working-age population in 2008 [31]. However, Fukuma S. et al. have reported that the national health guidance intervention was not associated with the reduction of cardiovascular risk such as diabetes [32]. Further research is needed to specify the subjects at high risk of metabolic disorders with or without obesity. Therefore, we believe that our study, which evaluated the risk factors according to BMI categories, is meaningful and will contribute to understanding the specific method of lifestyle interventions for improving metabolic disorders.

The strength of our study is its long period, large population, and consecutive data. However, there are several limitations. First, the diagnosis of diabetes was not based on hemoglobin A1c level. However, a previous study revealed that the correlation coefficient between FPG level and hemoglobin A1c level was 0.85 [33]. Thus, we considered it acceptable to substitute FPG levels and a self-reported history of diabetes for hemoglobin A1c level in order to assess the development of diabetes. Second, we might not evaluate the exact date of development of type 2 diabetes and exact information of a history of diabetes

because the subjects received a medical health checkup program once a year and we used the self-administered questionnaire to survey the history of diabetes. Third, it is well known that family history contributed to developing diabetes. Environmental factors including levels or types of incomes might have contributed to developing diabetes. Unfortunately, however, we had no data about family history of diabetes and details of levels or types of incomes. Forth, the participants consisted of relatively young Japanese people and this cohort was a selected working age cohort, which was composed of a single corporation. Therefore, it might not be obvious whether we can generalize what we found in this study to other generations and ethnic groups. We need to consider future studies to generalize our findings. We think possible studies, which follow up 10 years in the future and are composed of several companies, are necessary.

5. Conclusions

In clinical settings, it is crucial for us to perceive that the risk factors for diabetes differ among BMI categories in the Japanese population because it enables us to give advice tailored to each individual's BMI, which might help prevent the development of diabetes. In conclusion, the risk factors for the development of type 2 diabetes are different between the population with BMI < 22.0 kg/m² and the population with 22.0 ≤ BMI < 25.0 kg/m² or BMI ≥ 25.0 kg/m² in the Japanese population.

Author Contributions: Data curation, Y.S., H.O. and M.I.; discussion, H.O., M.H. (Masahide Hamaguchi), M.H. (Momoko Habu), K.K., H.M. and M.I.; writing—original draft preparation, Y.S.; writing—review and editing, M.F. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the local ethics committee of Panasonic Health Insurance Organization (Approval number: 2021-001, Approval date: 1 March 2021).

Informed Consent Statement: Not applicable.

Data Availability Statement: The datasets of our study are available on reasonable request through corresponding author.

Conflicts of Interest: Hiroshi Okada received personal fees from Mitsubishi Tanabe Pharma Corporation, MSD K.K., Sumitomo Dainippon Pharma Co., Ltd., Novo Nordisk Pharma Ltd., Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., Kyowa Hakko Kirin Company Ltd., Kissei Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd. and Sanofi K.K. M.H. (Masahide Hamaguchi) received grants from Ono Pharma Co., Ltd., AstraZeneca K.K., Oishi Kenko Inc., Yamada Bee Farm and received personal fees from AstraZeneca K.K., Ono Pharma Co., Ltd., Eli Lilly, Japan, Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corp., Daiichi Sankyo Co., Ltd., Sanofi K.K., Kowa Pharma Co., Ltd., outside the submitted work. M.F. received grants from Ono Pharma Co., Ltd., Oishi Kenko inc., Yamada Bee Farm, Mitsubishi Tanabe Pharma Corp., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corp., Kissei Pharma Co., Ltd., MSD K.K., Kyowa Kirin Co., Ltd., Astellas Pharma Inc., Sanofi K.K., Takeda Pharma Co., Ltd., Kowa Pharma Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Eli Lilly, Japan, K.K., Nippon Chemipharm Co., Ltd., Novo Nordisk Pharma Ltd., Terumo Corp., Tejin Pharma Ltd., Taisho Pharma Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Astellas Pharma Inc., and Johnson & Johnson K.K. Medical Co. and received personal fees from Nippon Boehringer Ingelheim Co., Ltd., Mitsubishi Tanabe Pharma Corp., Kissei Pharma Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Sanofi K.K., Takeda Pharma Co., Ltd., Abbott Japan Co., Ltd., Bayer Yakuhin, Ltd., Kowa Pharma Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., Ono Pharma Co., Ltd., Novo Nordisk Pharma Ltd. Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Taisho Pharma Co., Ltd., MSD K.K., Mochida Pharma Co., Ltd., AstraZeneca K.K., Abbott Japan Co., Ltd., Arkray Inc., Teijin Pharma Ltd., Nipro Corp., and Medtronic Japan Co., Ltd. outside the submitted work. The other authors have nothing to disclose.

References

1. Maskarinec, G.; Erber, E.; Grandinetti, A.; Verheus, M.; Oum, R.; Hopping, B.N.; Schmidt, M.M.; Uchida, A.; Juarez, D.T.; Hodges, K.; et al. Diabetes incidence based on linkages with health plans: The multiethnic cohort. *Diabetes* **2009**, *58*, 1732–1738. [[CrossRef](#)]
2. Mukai, N.; Doi, Y.; Ninomiya, T.; Hata, J.; Hirakawa, Y.; Fukuhara, M.; Iwase, M.; Kiyohara, Y. Cut-off values of fasting and post-load plasma glucose and HbA1c for predicting Type 2 diabetes in community-dwelling Japanese subjects: The Hisayama Study. *Diabet. Med.* **2012**, *29*, 99–106. [[CrossRef](#)]
3. Noda, M.; Kato, M.; Takahashi, Y.; Matsushita, Y.; Mizoue, T.; Inoue, M.; Tsugane, S.; Kadowaki, T. Fasting plasma glucose and 5-year incidence of diabetes in the JPHC diabetes study—Suggestion for the threshold for impaired fasting glucose among Japanese. *Endocr. J.* **2010**, *57*, 629–637. [[CrossRef](#)]
4. Fukuda, T.; Hamaguchi, M.; Kojima, T.; Hashimoto, Y.; Ohbora, A.; Kato, T.; Nakamura, N.; Fukui, M. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. *Liver Int.* **2016**, *36*, 275–283. [[CrossRef](#)] [[PubMed](#)]
5. Kodama, S.; Saito, K.; Yachi, Y.; Asumi, M.; Sugawara, A.; Totsuka, K.; Saito, A.; Sone, H. Association between serum uric acid and development of type 2 diabetes. *Diabetes Care* **2009**, *32*, 1737–1742. [[CrossRef](#)] [[PubMed](#)]
6. Heianza, Y.; Hara, S.; Arase, Y.; Saito, K.; Totsuka, K.; Tsuji, H.; Kodama, S.; Hsieh, S.D.; Yamada, N.; Kosaka, K.; et al. Low serum potassium levels and risk of type 2 diabetes: The Toranomon Hospital Health Management Center Study 1 (TOPICS 1). *Diabetologia* **2011**, *54*, 762–766. [[CrossRef](#)]
7. Heianza, Y.; Arase, Y.; Tsuji, H.; Saito, K.; Amakawa, K.; Hsieh, S.D.; Kodama, S.; Shimano, H.; Yamada, N.; Hara, S.; et al. Low lung function and risk of type 2 diabetes in Japanese men: The Toranomon Hospital Health Management Center Study 9 (TOPICS 9). *Mayo Clin. Proc.* **2012**, *87*, 853–861. [[CrossRef](#)] [[PubMed](#)]
8. Kunutsor, S.K.; Apekey, T.A.; Walley, J.; Kain, K. Ferritin levels and risk of type 2 diabetes mellitus: An updated systematic review and meta-analysis of prospective evidence. *Diabetes Metab. Res. Rev.* **2013**, *29*, 308–318. [[CrossRef](#)] [[PubMed](#)]
9. Doi, Y.; Kiyohara, Y.; Kubo, M.; Ninomiya, T.; Wakugawa, Y.; Yonemoto, K.; Iwase, M.; Iida, M. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: The Hisayama Study. *Diabetes Care* **2005**, *28*, 2497–2500. [[CrossRef](#)]
10. Wang, X.; Bao, W.; Liu, J.; Ouyang, Y.Y.; Wang, D.; Rong, S.; Xiao, X.; Shan, Z.L.; Zhang, Y.; Yao, P.; et al. Inflammatory markers and risk of type 2 diabetes: A systematic review and meta-analysis. *Diabetes Care* **2013**, *36*, 166–175. [[CrossRef](#)]
11. Doi, Y.; Kubo, M.; Yonemoto, K.; Ninomiya, T.; Iwase, M.; Tanizaki, Y.; Shikata, K.; Iida, M.; Kiyohara, Y. Liver enzymes as a predictor for incident diabetes in a Japanese population: The Hisayama study. *Obesity* **2007**, *15*, 1841–1850. [[CrossRef](#)]
12. Sato, K.K.; Hayashi, T.; Nakamura, Y.; Harita, N.; Yoneda, T.; Endo, G.; Kambe, H. Liver enzymes compared with alcohol consumption in predicting the risk of type 2 diabetes: The Kansai Healthcare Study. *Diabetes Care* **2008**, *31*, 1230–1236. [[CrossRef](#)]
13. Yoshizawa, S.; Heianza, Y.; Arase, Y.; Saito, K.; Hsieh, S.D.; Tsuji, H.; Hanyu, O.; Suzuki, A.; Tanaka, S.; Kodama, S.; et al. Comparison of different aspects of BMI history to identify undiagnosed diabetes in Japanese men and women: Toranomon Hospital Health Management Center Study 12 (TOPICS 12). *Diabet. Med.* **2014**, *31*, 1378–1386. [[CrossRef](#)]
14. Sakurai, M.; Nakamura, K.; Miura, K.; Takamura, T.; Yoshita, K.; Nagasawa, S.; Morikawa, Y.; Ishizaki, M.; Kido, T.; Naruse, Y.; et al. Self-reported speed of eating and 7-year risk of type 2 diabetes mellitus in middle-aged Japanese men. *Metabolism* **2012**, *61*, 1566–1571. [[CrossRef](#)] [[PubMed](#)]
15. Heianza, Y.; Kato, K.; Fujihara, K.; Tanaka, S.; Kodama, S.; Hanyu, O.; Sato, K.; Sone, H. Role of sleep duration as a risk factor for Type 2 diabetes among adults of different ages in Japan: The Niigata Wellness Study. *Diabet Med.* **2014**, *31*, 1363–1367. [[CrossRef](#)] [[PubMed](#)]
16. Sone, H.; Mizuno, S.; Ohashi, Y.; Yamada, N. Type 2 diabetes prevalence in Asian subjects. *Diabetes Care* **2004**, *27*, 1251–1252. [[CrossRef](#)] [[PubMed](#)]
17. Yabe, D.; Kuroe, A.; Watanabe, K.; Iwasaki, M.; Hamasaki, A.; Hamamoto, Y.; Harada, N.; Yamane, S.; Lee, S.; Murotani, K.; et al. Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients. *J. Diabetes Complicat.* **2015**, *29*, 413–421. [[CrossRef](#)] [[PubMed](#)]
18. Chiu, M.; Austin, P.C.; Manuel, D.G.; Shah, B.R.; Tu, J.V. Deriving ethnic-specific BMI cutoff points for assessing diabetes risk. *Diabetes Care* **2011**, *34*, 1741–1748. [[CrossRef](#)] [[PubMed](#)]
19. Nijhuis, J.; Rensen, S.S.; Slaats, Y.; van Dielen, F.M.; Buurman, W.A.; Greve, J.W. Neutrophil activation in morbid obesity, chronic activation of acute inflammation. *Obesity* **2009**, *17*, 2014–2018. [[CrossRef](#)]
20. Tokunaga, K.; Matsuzawa, Y.; Kotani, K.; Keno, Y.; Kobatake, T.; Fujioka, S.; Tarui, S. Ideal body weight estimated from the body mass index with the lowest morbidity. *Int. J. Obes.* **1991**, *15*, 1–5.
21. Campbell, P.J.; Carlson, M.G. Impact of obesity on insulin action in NIDDM. *Diabetes* **1993**, *42*, 405–410. [[CrossRef](#)]
22. Bogardus, C.; Lillioja, S.; Mott, D.M.; Hollenbeck, C.; Reaven, G. Relationship between degree of obesity and in vivo insulin action in man. *Am. J. Physiol.* **1985**, *248*, E286–E291. [[PubMed](#)]
23. Esteve, E.; Ricart, W.; Fernández-Real, J.M. Adipocytokines and insulin resistance: The possible role of lipocalin-2, retinol binding protein-4, and adiponectin. *Diabetes Care* **2009**, *32*, S362–S367. [[CrossRef](#)] [[PubMed](#)]
24. Lorenzo, M.; Fernández-Veledo, S.; Vila-Bedmar, R.; Garcia-Guerra, L.; De Alvaro, C.; Nieto-Vazquez, I. Insulin resistance induced by tumor necrosis factor- α in myocytes and brown adipocytes. *J. Anim. Sci.* **2008**, *86*, E94–E104. [[CrossRef](#)] [[PubMed](#)]

25. Alberti, K.G.M.M.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.; James, W.P.T.; Loria, C.M.; Smith, S.C.J. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* **2009**, *120*, 1640–1645. [[PubMed](#)]
26. Willi, C.; Bodenmann, P.; Ghali, W.A.; Faris, P.D.; Cornuz, J. Active smoking and the risk of type 2 diabetes: A systematic review and meta-analysis. *JAMA* **2007**, *298*, 2654–2664. [[CrossRef](#)]
27. Kodama, K.; Tojjar, D.; Yamada, S.; Toda, K.; Patel, C.J.; Butte, A.J. Ethnic differences in the relationship between insulin sensitivity and insulin response: A systematic review and meta-analysis. *Diabetes Care* **2013**, *36*, 1789–1796. [[CrossRef](#)]
28. Ohkuma, T.; Hirakawa, Y.; Nakamura, U.; Kiyohara, Y.; Kitazono, T.; Ninomiya, T. Association between eating rate and obesity: A systematic review and meta-analysis. *Int. J. Obes.* **2015**, *39*, 1589–1596. [[CrossRef](#)] [[PubMed](#)]
29. Saito, Y.; Kajiyama, S.; Nitta, A.; Miyawaki, T.; Matsumoto, S.; Ozasa, N.; Kajiyama, S.; Hashimoto, Y.; Fukui, M.; Imai, S. Eating Fast Has a Significant Impact on Glycemic Excursion in Healthy Women: Randomized Controlled Cross-Over Trial. *Nutrients* **2020**, *12*, 2767. [[CrossRef](#)]
30. Han, M. The Dose-Response Relationship between Alcohol Consumption and the Risk of Type 2 Diabetes among Asian Men: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. *J. Diabetes Res.* **2020**, *24*, 1032049. [[CrossRef](#)]
31. Tsushita, K.; Hosler, A.S.; Miura, K.; Ito, Y.; Fukuda, T.; Kitamura, A.; Tataru, K. Rationale and Descriptive Analysis of Specific Health Guidance: The Nationwide Lifestyle Intervention Program Targeting Metabolic Syndrome in Japan. *J. Atheroscler. Thromb.* **2018**, *25*, 308–322. [[CrossRef](#)]
32. Fukuma, S.; Iizuka, T.; Ikenoue, T.; Tsugawa, Y. Association of the National Health Guidance Intervention for Obesity and Cardiovascular Risks with Health Outcomes among Japanese Men. *JAMA Intern. Med.* **2020**, *180*, 1630–1637. [[CrossRef](#)]
33. Ito, C.; Maeda, R.; Ishida, S.; Sasaki, H.; Harada, H. Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c. *Diabetes Res. Clin. Pract.* **2000**, *50*, 225–230. [[CrossRef](#)]